Biomatter develops proteins and enzymes with Intelligent Architecture™ for health and sustainable manufacturing. The company provides solutions from initial concept to protein production.

Biomatter

Biomatter | 4,464 followers on LinkedIn. Creating proteins with Intelligent Architecture™ for health and sustainable manufacturing | Biomatter (previously called Biomatter Designs) is a synthetic biology company that creates new proteins for health and sustainable manufacturing applications. The company has developed the Intelligent Architecture™ platform that addresses limitations of current engineering approaches to unlock completely new horizons for protein design and development.

Dr. NSc.

Dr. NSc.Eng. Luciano Pighinelli

Head of Computational Chemistry at Biomatter | Creating proteins with Intelligent Architecture™

Masoud Kazemi

Chief Scientific Officer at Biomatter

Linas Zakrys

Principal at UVC Partners

Oliver Schoppe

Biomatter is heading to Sweden for #BioEurope2024 ! We're looking forward to connecting with industry leaders and exchanging the latest insights in the biotech field. Indrė will be there to explore how Biomatter can support streamlining enzyme-based processes or drive forward new product ideas. Make sure to reach out and find a time to meet her! #Biomatter #ProteinArchitects #IntelligentArchitecture #EnzymeDevelopment #EnzymeOptimization #EnzymeEngineering

Throwback to last week… and WOW 🤩 #InvestorCamp and #StartupFair had us absolutely buzzing. From panels, nonstop networking, startup pitches, and yes, gin-infused drinks — the energy was OFF THE CHARTS. 💥 Here’s the tea: ✨ Investor Camp: Donatas Keras sat down with Juozas Nainys and Laurynas Karpus to talk life sciences + AI (and blew our minds) x Atrandi Biosciences x Biomatter ✨ Practica’s Aperitif? Drinks + vibes on point. ✨ Investor Camp Dinner - conversations flowing, connections made. ✨ Next day = all about startups. Arvydas Bloze hit the stage with Justinas Baranovskis to share the deets on their fresh Series B round x Ovoko \ RRR.LT ✨ Wrapped up with the ultimate Founders & Funders party — over 100 guests, co-hosted with FIRSTPICK , Earlybird Digital East Fund, and Northzone . Unreal. 📷 Here are some moments we've made together: https://lnkd.in/gm3WttVN Huge shoutout to all our friends & partners Lithuanian Private Equity and Venture Capital Association , Startup Lithuania , Lithuanian Business Angel Network LitBAN , and every single person we met. ❤️ Catch you at the next one.

Practica Capital

Exciting news from the world of computational protein engineering! The 2024 Nobel Prize in Chemistry has been awarded to David Baker, Demis Hassabis, and John M. Jumper for their pioneering contributions to protein design and structure prediction. Their work is transforming how we understand and manipulate proteins, creating entirely new possibilities in medicine, materials science, and beyond. 🚀 We couldn't be more inspired by this achievement, which points to a future where biology is reshaped by engineering proteins, including enzymes, playing a crucial role across industries - from pharmaceuticals and chemical manufacturing to food or life sciences. We're excited to be a part of this computational protein engineering journey, pushing the boundaries of enzyme development whilst creating a more sustainable and healthier world.

Let's meet in Milan this week. Drop me a message if you're attending the conference! 🔬🛸 #CPHI2024 #CPHI #Biomatter #EnzymeEngineering #IntelligentArchitecture

Ieva Lingytė

Biomatter team is heading to London this week! 🇬🇧 We're excited to dive into how protein-powered technologies are shaping a more sustainable, efficient food system while also driving innovation in novel food ingredients space. Our team members, Matthew and Ieva , are eager to connect and discuss how our Intelligent Architecture can help tackle enzyme-related challenges in the food industry. Let's connect and have a chat! #FutureFoodTech #EnzymeEngineering #IntelligentArchitecture #EnzymeDesign #Biomatter #ProteinArchitects

Get Ready for Investor Camp Next Week! 🚀 We’re excited to introduce one of the panels: The Intersection of Life Sciences and AI — a deep dive into one of the most groundbreaking and transformative fields today. This is your opportunity to hear directly from visionary founders who are shaping the future of healthcare, biotechnology, and artificial intelligence. Discover how these industries are converging to fuel game-changing innovations. 🔥 Meet the Panelists: Juozas Nainys , Co-Founder & CEO at Atrandi Biosciences Laurynas Karpus , Co-Founder & CEO at Biomatter The discussion will be moderated by our partner, Donatas Keras . 👉 Get your ticket: https://lnkd.in/dvyHuiiP P.S. As the event comes to a close, we'll invite all attendees for a pre-dinner networking gathering in a relaxed, informal setting - Aperitif by Practica. Looking forward to seeing you there! 👋

📣 Biomatter raises a €6.5 million round to unlock the power of generative AI for enzyme design 🎉 At Biomatter, we believe that the limitless potential to design new enzymes will contribute to building a better future for everyone. The new funding brings us one step closer to realizing our vision. We are excited to announce the new €6.5 million financing round to further expand the unique capabilities of our platform and create new-to-world enzymes. This achievement would not have been possible without the incredible dedication of the entire Protein Architects team at Biomatter , who consistently go above and beyond to reimagine what's possible with enzymes. The investment round was led by Inventure and UVC Partners , joined by existing investors Practica Capital and Metaplanet , as well as esteemed business angels and industry experts. For more insights, check out the article from SynBioBeta in the comments. #Biomatter #ProteinaArchitects #EnzymeDevelopment

After an incredible week at #GRC Biocatalysis 2024, I wanted to take a few days to gather my thoughts and capture learnings from what is one of my favourite conferences in the calendar. It was a pleasure to be able to present what Biomatter is doing on the stage next to established folks like Stefan Lutz, who did an excellent intro to mRNA on my behalf as well as the other industry folks- Martin Hayes , Kai Baldenius , Hans Iding , Richard Fox and Lara Zetzsche . As Biomatter looks to change the way we think about engineering enzymes it was exciting to share tangible examples of processes developed from our tech, all whilst having some of the best minds in this space meet me with enthusiasm and curiosity. All thanks of course to Sabine Flitsch and Carlos for the invite to speak and for organising a marvellous event. Looking forward to the next edition with Mélanie Hall , Radka Snajdrova already with of course my congratulations to my friends Scott France and Dörthe for being elected to run the show in 2028! So- what did I take away that maybe some in my network want to get their brains ticking over. 1) mRNA is here to stay, and we need tools and raw materials to meet the future demand. >30 tonnes of RNA materials expected to be needed to meet 2030 demand. Fortunately this is something Biomatter has been ahead of the curve on for a while and we will continue to lead the way 2) Pharma is continuing to focus on PMI, but at the same time we are still seeing glucose used as the default hydride source. Maybe it’s time to change that. There’s some obvious reasons we still rely on GDH, what innovations could replace this workhorse? 3) Folks are very excited about the rate of change in the enzyme ML/AI space for accessing new enzymes. With new models coming out so regularly, how are we keeping on top of what the best in class for both academic and industry use. One major challenge remains the accuracy of a lot of the current models in predicting functional enzymes. While some folks are pushing hard down the “more data” to train on track, others are continuing to show that blending physics with AI gives the best performance in terms of speed and accuracy. A bonus thought, the complexity of reactions we are able to unlock is increasing all the time, from modified nucleosides ( Sarah Lovelock ) to controlled radical mechanisms,( Yang Yang ). Echoing the thoughts of Jared Lewis as to what the next “do it all platform” enzyme will look like. What the most needed reaction we cannot yet do reliably with enzymes? Lastly, the GRC is not just about the latest and greatest science, there’s always old and new friends and catch up with. A pleasure as always ( Rachel Heath , Christian Schnepel , Nicholas Turner , John Woodley , Bethany Hogg Bo Couture , and Bettina Nestl amongst others I have surely forgotten along with the networking rockstar that is Johanna Thompson (fd Löfgren) Already looking forward to the next edition.

Matthew Thompson

Biomatter is back on the road! 🚀 Next week, don't miss our VP - Programs, Matthew Thompson , at the Gordon Research Conference - Biocatalysis, where he will showcase how Intelligent Architecture™ enables production from novel and improved synthetic routes to target molecules through novel reaction steps. Catch Matthew at the conference to dive deeper into our novel enzyme engineering approach! #GordonResearchConference2024 #Biocatalysis #ProteinArchitects #EnzymeDesign #EnzymeDiscovery #EnzymeEngineering #LYNXEnzymeOptimization

Make sure to catch Indrė Surgelytė and explore how Biomatter is reshaping biology! 🔎

news impact assignment basic	general
public peers	general	Nov 11, 2024 6:45 PM	f7794b5b
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 11, 2024 6:45 PM	4c36ce66
crunchbase trigger	general	Nov 11, 2024 6:45 PM	fe71e4ec
crunchbase profile	general
li profile	general	Nov 11, 2024 6:45 PM	fd00615e
translate crunchbase fundingrounds	general
peers	general	Nov 11, 2024 6:45 PM	d98dbc68
news basic	general	Nov 11, 2024 6:45 PM	d5f13b26
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

BIOM

COM:BIOMATTER

Biomatter